Karyopharm Therapeutics (KPTI) Short term Debt (2025)

Karyopharm Therapeutics (KPTI) reported Short term Debt of $21.0 million for Q4 2025, up 68.08% quarter-over-quarter from $12.5 million in Q3 2025.

Karyopharm Therapeutics (KPTI) Short term Debt (2025) Analysis & Trends

Karyopharm Therapeutics has reported Short term Debt for 1 years, with the latest figure at $21.0 million in Q4 2025.

For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $21.0 million; the trailing twelve-month figure through Dec 2025 stood at $21.0 million (changed N/A YoY), and the FY2025 full-year result was $21.0 million, changed N/A from the prior year.
Short term Debt for Q4 2025 stood at $21.0 million, up from $12.5 million in the prior quarter.
The five-year high for Short term Debt was $21.0 million in Q4 2025, with the low at $6.2 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Karyopharm Therapeutics	95.31 Mn	31.56 Mn	32.74 Mn

Download Data